# Anti-cancer effect of palmitic acid against the endometrial cancer progression via inducing ferroptosis

**Authors:** Shuting Lan, Xiaomei Sun, Qiyuan Bo, Suriguga Wang, Yifan Qin, Jianying Mao

PMC · DOI: 10.1016/j.bbrep.2026.102499 · Biochemistry and Biophysics Reports · 2026-02-10

## TL;DR

Palmitic acid inhibits endometrial cancer progression by inducing a type of cell death called ferroptosis, both in lab and animal models.

## Contribution

This study reveals that palmitic acid suppresses endometrial cancer through ferroptosis activation, offering a novel therapeutic strategy.

## Key findings

- Palmitic acid reduced cancer cell viability, migration, invasion, and epithelial-mesenchymal transition while inducing cell cycle arrest and apoptosis.
- In xenograft models, palmitic acid significantly suppressed tumor growth.
- Transcriptomic and metabolomic analyses confirmed that palmitic acid's anti-cancer effects are mediated through ferroptosis activation.

## Abstract

The critical role of metabolic reprogramming as a potential therapeutic target in the management of endometrial cancer (EC) progression requires further investigation. This study investigated the anti-cancer effect of palmitic acid (PA) on EC progression using cellular and xenograft models, combined with integrated transcriptomic and metabolomic analyses to elucidate the molecular pathways through which PA induces ferroptosis and inhibits tumor growth.

The anti-cancer effects of PA were assessed through comprehensive in vitro assays, including cell viability, proliferation, migration, invasion, adhesion, clonogenicity, cell-cycle distribution, apoptosis, and epithelial-mesenchymal transition (EMT). In vivo, the therapeutic efficacy of PA was evaluated using a xenograft mouse model. Transcriptomic and metabolomic profiling identified differentially expressed genes (DEGs) and metabolites, with Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses further exploring PA's mechanistic impact.

PA significantly reduced the viability, migration, invasion, clonogenic potential, and EMT of EC cells, while inducing cell-cycle arrest and apoptosis. In xenograft models, PA effectively suppressed tumor growth. Mechanistically, transcriptomic and metabolomic analyses, together with changes in ferroptosis-related markers, indicated that PA exerts its anti-cancer effects at least in part through ferroptosis activation. This conclusion was further supported by multiple ferroptosis hallmarks and ferrostatin-1 rescue, which substantially attenuated PA-induced phenotypic and biochemical alterations.

PA suppressed EC progression by inducing ferroptosis, providing novel mechanistic insights into PA's anti-cancer properties and underscoring its potential as a therapeutic candidate for EC treatment.

•PA reduced the viability, migration, invasion, clonogenic potential, and EMT of EC cells, while inducing cell cycle arrest and apoptosis.•In xenograft models, PA effectively suppressed tumor growth.•PA exerts its anti-cancer effects primarily through the activation of ferroptosis.

PA reduced the viability, migration, invasion, clonogenic potential, and EMT of EC cells, while inducing cell cycle arrest and apoptosis.

In xenograft models, PA effectively suppressed tumor growth.

PA exerts its anti-cancer effects primarily through the activation of ferroptosis.

## Linked entities

- **Chemicals:** palmitic acid (PubChem CID 985)
- **Diseases:** endometrial cancer (MONDO:0002447)

## Full-text entities

- **Genes:** STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) [NCBI Gene 3156] {aka LDLCQ3, LGMDR28, MYPLG}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, FASN (fatty acid synthase) [NCBI Gene 2194] {aka FAS, OA-519, SDR27X1}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451] {aka PEK, PERK, WRS}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657] {aka CCBR1, xCT}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, ERN1 (endoplasmic reticulum to nucleus signaling 1) [NCBI Gene 2081] {aka IRE1, IRE1P, IRE1a, hIRE1p}, HSF1 (heat shock transcription factor 1) [NCBI Gene 3297] {aka HSTF1}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, ZEB1 (zinc finger E-box binding homeobox 1) [NCBI Gene 6935] {aka AREB6, BZP, DELTAEF1, FECD6, NIL2A, PPCD3}, DNTT (DNA nucleotidylexotransferase) [NCBI Gene 1791] {aka TDT}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, SNAI2 (snail family transcriptional repressor 2) [NCBI Gene 6591] {aka SLUG, SLUGH, SLUGH1, SNAIL2, WS2D}, SCD (stearoyl-CoA desaturase) [NCBI Gene 6319] {aka FADS5, MSTP008, SCD1, SCDOS, hSCD1}, CYP2E1 (cytochrome P450 family 2 subfamily E member 1) [NCBI Gene 1571] {aka CPE1, CYP2E, P450-J, P450C2E}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, VIM (vimentin) [NCBI Gene 7431], PRKCZ (protein kinase C zeta) [NCBI Gene 5590] {aka PKC-ZETA, PKC2}, ATF6 (activating transcription factor 6) [NCBI Gene 22926] {aka ACHM7, ATF6A, ATP6alpha}, PEBP1 (phosphatidylethanolamine binding protein 1) [NCBI Gene 5037] {aka HCNP, HCNPpp, HEL-210, HEL-S-34, HEL-S-96, PBP}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720] {aka HMD, IFAP2, SREBP1, bHLHd1}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, DNASE2 (deoxyribonuclease 2, lysosomal) [NCBI Gene 1777] {aka AIPCS, DNASE2A, DNL, DNL2}, ALOX15 (arachidonate 15-lipoxygenase) [NCBI Gene 246] {aka 12-LOX, 15-LOX, 15-LOX-1, LOG15}, MUSK (muscle associated receptor tyrosine kinase) [NCBI Gene 4593] {aka CMS9, FADS}, GPAM (glycerol-3-phosphate acyltransferase, mitochondrial) [NCBI Gene 57678] {aka GPAT, GPAT1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** neurodegenerative disorders (MESH:D019636), chronic inflammation (MESH:D007249), melanoma (MESH:D008545), oral and prostate cancer (MESH:D011471), metastasis (MESH:D009362), hyperglycemia (MESH:D006943), metabolic disturbances (MESH:D024821), Dyslipidemia (MESH:D050171), deaths (MESH:D003643), EC (MESH:D016889), colorectal cancer (MESH:D015179), atherosclerosis (MESH:D050197), pancreatic cancer (MESH:D010190), Mitochondrial (MESH:D028361), TCA (MESH:C564762), diabetes (MESH:D003920), Tumor (MESH:D009369), MSI-H (MESH:D053842), cytotoxicity (MESH:D064420), insulin resistance (MESH:D007333), MAFLD (MESH:D005234), gastric, liver, cervical, neuroblastoma, breast, and colorectal cancers (MESH:D013274), PA (MESH:D011015), Obesity (MESH:D009765), carcinogenesis (MESH:D063646), oral carcinoma (MESH:D009062), dislocation (MESH:D004204), metabolic disorders (MESH:D008659), necrosis (MESH:D009336), hypoxia (MESH:D000860)
- **Chemicals:** PI (MESH:D011419), pyruvate (MESH:D019289), methionine (MESH:D008715), A939572 (-), paraffin (MESH:D010232), olive oil (MESH:D000069463), ferrostatin-1 (MESH:C573944), crystal violet (MESH:D005840), methanol (MESH:D000432), sulfur (MESH:D013455), POA (MESH:C008757), H&amp;E (MESH:D006371), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MESH:C022616), PUFA (MESH:D005231), JC-1 (MESH:C068624), P (MESH:D010758), Orlistat (MESH:D000077403), oxygen (MESH:D010100), cystine (MESH:D003553), penicillin (MESH:D010406), formazan (MESH:D005562), aspartate (MESH:D001224), dUTP (MESH:C027078), DPBS (MESH:C012939), thiamine (MESH:D013831), NADPH (MESH:D009249), N (MESH:D009584), MDA (MESH:D015104), amino acids (MESH:D000596), MTT (MESH:C070243), F12 (MESH:C007782), uranyl acetate (MESH:C005460), TAG (MESH:D014280), phosphatidic acid (MESH:D010712), Triton X-100 (MESH:D017830), MUFAs (MESH:D005229), streptomycin (MESH:D013307), TCA (MESH:D014233), lipid hydroperoxides (MESH:D008054), carbohydrates (MESH:D002241), arginine (MESH:D001120), FAs (MESH:D005227), pentose phosphate (MESH:D010428), alanine (MESH:D000409), cocoa butter (MESH:C052387), tyrosine (MESH:D014443), PL (MESH:D010743), ATP (MESH:D000255), CO2 (MESH:D002245), ALA (MESH:D017962), GSH (MESH:D005978), PA (MESH:D019308), free fatty acid (MESH:D005230), DCFH-DA (MESH:C029569), Iron (MESH:D007501), lipid (MESH:D008055), Cysteine (MESH:D003545), AA (MESH:D016718), stearic acid (MESH:C031183), paraformaldehyde (MESH:C003043)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Enterovirus C (no rank) [taxon 138950], Homo sapiens (human, species) [taxon 9606], PX clade (clade) [taxon 569578]
- **Mutations:** cysteine/methionine, C0009S, alanine/aspartate, C0071S
- **Cell lines:** Ishikawa — Homo sapiens (Human), Type I endometrial adenocarcinoma, Cancer cell line (CVCL_2529)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12914859/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12914859/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12914859/full.md

---
Source: https://tomesphere.com/paper/PMC12914859